Literature DB >> 27823756

Comparison of pulmonary function tests and perioperative outcomes after robotic-assisted pulmonary lobectomy vs segmentectomy.

Maria F Echavarria1, Anna M Cheng1, Frank O Velez-Cubian2, Emily P Ng1, Carla C Moodie3, Joseph R Garrett3, Jacques P Fontaine4, Lary A Robinson4, Eric M Toloza5.   

Abstract

BACKGROUND: Lobectomy is standard treatment for early-stage lung cancer, but sublobar resection remains debated. We compared outcomes after robotic-assisted video-assisted thoracoscopic (R-VATS) segmentectomy vs lobectomy.
METHODS: We retrospectively analyzed data from 251 consecutive patients who underwent R-VATS lobectomy (n = 208) or segmentectomy (n = 43) by a single surgeon over 36 months. Pulmonary function tests and perioperative outcomes were compared using Chi-squared test, unpaired Student t test, or Kruskal-Wallis test, with significance at P ≤ .05.
RESULTS: Intraoperative complications were not significantly different, but median operative times were longer for R-VATS segmentectomies (P < .01). Postoperative complications were not significantly different, except for increased rates of pneumothorax after chest tube removal (P = .032) and of effusions or empyema (P = .011) after R-VATS segmentectomies. Predicted changes for forced expiratory volume in 1 second and diffusion constant of the lung for carbon monoxide are significantly less after R-VATS segmentectomy (P < .001).
CONCLUSIONS: R-VATS segmentectomy should be considered as an alternative to lobectomy for conserving lung function in respiratory-compromised lung cancer patients, although oncologic efficacy remains undetermined. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lobectomy; Lung cancer; Outcomes; Pulmonary function; Robotic surgery; Segmentectomy

Mesh:

Year:  2016        PMID: 27823756     DOI: 10.1016/j.amjsurg.2016.09.017

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  8 in total

1.  Technique of robotic segmentectomy.

Authors:  Benjamin Wei; Robert Cerfolio
Journal:  J Vis Surg       Date:  2017-10-14

Review 2.  VATS segmentectomy: past, present, and future.

Authors:  Seshiru Nakazawa; Kimihiro Shimizu; Akira Mogi; Hiroyuki Kuwano
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-12-18

3.  Lobectomy is superior to segmentectomy for peripheral high grade non-small cell lung cancer ≤2 cm.

Authors:  Mirza Zain Baig; Syed S Razi; Joanna F Weber; Cliff P Connery; Faiz Y Bhora
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 2.895

4.  Three-dimensional (3D)- computed tomography bronchography and angiography combined with 3D-video-assisted thoracic surgery (VATS) versus conventional 2D-VATS anatomic pulmonary segmentectomy for the treatment of non-small cell lung cancer.

Authors:  Xiao-Wei She; Yun-Bin Gu; Chun Xu; Chang Li; Cheng Ding; Jun Chen; Jun Zhao
Journal:  Thorac Cancer       Date:  2018-01-03       Impact factor: 3.500

Review 5.  Prognosis of segmentectomy in the treatment of stage IA non-small cell lung cancer.

Authors:  Wenliang Bai; Shanqing Li
Journal:  Oncol Lett       Date:  2020-11-25       Impact factor: 2.967

6.  Pulmonary function changes after thoracoscopic lobectomy versus intentional thoracoscopic segmentectomy for early-stage non-small cell lung cancer.

Authors:  Liang Chen; Zhitao Gu; Boyu Lin; Weimin Wang; Ning Xu; Yuan Liu; Chunyu Ji; Wentao Fang
Journal:  Transl Lung Cancer Res       Date:  2021-11

7.  Report on 153 sequential three-incision robotic-assisted pulmonary resections by a single surgeon: technical details and learning curve.

Authors:  Muyun Peng; Xiang Wang; Chen Chen; Sichuang Tan; Wenliang Liu; Fenglei Yu
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

8.  Novel strategy to treat lung metastases: Hybrid therapy involving surgery and radiofrequency ablation.

Authors:  Takaaki Hasegawa; Hiroaki Kuroda; Noriaki Sakakura; Yozo Sato; Shohei Chatani; Shinichi Murata; Hidekazu Yamaura; Takeo Nakada; Yuko Oya; Yoshitaka Inaba
Journal:  Thorac Cancer       Date:  2021-06-09       Impact factor: 3.500

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.